CA2931039C — Compositions and methods for treatment of ocular inflammation and pain
Assigned to Panag Pharma Inc · Expires 2022-07-12 · 4y expired
What this patent protects
The disclosure provides methods of treatment of ocular inflammation or neuropathic pain in a subject in need thereof, comprising administering to the subject in need thereof a CB2 target agent, a cannabimimetic agent (such as a non-psychotropic cannabimimetic agent) or a combinat…
USPTO Abstract
The disclosure provides methods of treatment of ocular inflammation or neuropathic pain in a subject in need thereof, comprising administering to the subject in need thereof a CB2 target agent, a cannabimimetic agent (such as a non-psychotropic cannabimimetic agent) or a combination thereof. The agent is optionally a cannabinoid, such as a non-psychotropic cannabinoid or a synthetic cannabinoid. In certain embodiments, the non-psychotropic phytocannabinoid is ß-caryophyllene or cannabidiol [CBD] and the synthetic cannabinoid is HU-433, HU-308, or a modified CBD such as CBD-DMH. The disclosure also provides ocular pharmaceutical compositions containing the CB2 target agents or cannabimimetic agents such as non-psychotropic cannabimimetic agents described herein.
Drugs covered by this patent
- Miebo (PERFLUOROHEXYLOCTANE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.